Jeff Fairman

Jeff has over 20 years of experience in the biotech arena having led the research at multiple platform companies that he co-founded resulting in multiple clinical candidates and approved vaccines and immunotherapeutics. Prior to Vaxcyte, Jeff was the founder and Vice President of Research at Juvaris BioTherapeutics, whose immunotherapeutic & vaccine adjuvant platform yielded multiple animal health products launched by its alliance partner Bayer HealthCare, including Zelnate® and Victrio®. While at Juvaris, Jeff was the recipient of major grant funding from multiple sources, including NIH and NCI, supporting substantial pre-clinical programs and multiple clinical studies. He was responsible for research activities resulting in multiple clinical candidates and the approved animal health products. Prior to Juvaris, Jeff was the Director of Pharmacogenomics at Clingenix and Senior Scientist at Valentis. Dr. Fairman has a Ph.D. in Chemistry and his postdoctoral training was in the genetics of leukemia at MD Anderson Cancer Center. Jeff enjoys spending time with his wife and daughter and has put his amateur taekwondo career on hold, for the time being, to be courtside rooting for his daughter’s school and club volleyball teams.